Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SPRY
SPRY | US
8.29
USD-0.01
-0.12%
SPRY | US
Loading StockChartView...
About SPRY
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
8.29
Open
8.25
High
8.41
Low
7.95
ARS Pharmaceuticals Inc. a biopharmaceutical company develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions including anaphylaxis. The company was founded in 2015 and is based in San Diego California.
View LessSPRY | US
Risk
53.8
Sharpe
-0.72
Luna's Score
46/100
Recommendation
Hold
Luna says (SPRY | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
46.7%1 month
53.8%3 months
50.6%6 months
73.5%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
7.20
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
-9.88
Ent. to rev.
2.66K
PEG
-
Other Fundamentals
EBITDA
-56.67M
MarketCap
803.65M
MarketCap(USD)
803.65M
Div. yield
-
Op. margin
-3.07K
Erngs. growth
-
Rev. growth
4.90K
Ret. on equity
-19.34
Short ratio
10.96
Short perc.
21.57
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.81
Range1M
1.09
Range3M
3.68
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.25
Price X volume
16.55M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -9.88 | 0.53 | Cheaper |
| Ent. to Revenue | 2,663.02 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.20 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 50.60 | 72.80 | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 803.65M | 3.66B | Emerging |
